November 21, 2025

Company name	Sysmex Corporation
Representative	President Kaoru Asano (Stock Code: 6869)
Inquiries	Takashi Hatakeda, Executive Vice President of Corporate Communication Division (Telephone: +81-78-265-0500)

Notice Concerning Absorption-Type Merger (Simplified/Short-Form Merger) of Wholly Owned Subsidiary

Sysmex Corporation (the "Company") hereby announces that a meeting of the Board of Directors held on November 21, 2025 resolved to absorb its wholly owned subsidiary, Sysmex Medica Co., Ltd. (hereinafter "Sysmex Medica") and have entered into a merger agreement.

Since this is a simplified absorption-type merger involving a wholly owned subsidiary, some disclosure items and details have been omitted.

1. Purpose of the merger

Sysmex Medica is a company that assembles units of diagnostic instruments. The Company decided to absorb Sysmex Medica to optimize the equipment production process within the Group and to enhance efficiency and productivity.

2. Summary of the merger

(1) Timetable for the merger

Date of resolution at the meeting of the Board of Directors	November 21, 2025
Date of conclusion of the agreement	November 21, 2025
Commencement date (Effective date)	April 1, 2026 (scheduled)

(Note) Since this is a simplified merger pursuant to Article 796, paragraph (2) of the Companies Act of Japan for the Company and is also a short-form merger pursuant to Article 784, paragraph (1) of the Companies Act for the Sysmex Medica, each company will not hold a general meeting of shareholders to approve the merger agreement.

(2) Form of the merger

The merger will be conducted as an absorption-type merger, with the Company as the surviving company, and Sysmex Medica will be dissolved.

(3) Details of allotment related to the merger

Since the merger is a merger with a wholly owned subsidiary of the Company, there will be no issuance of new shares, no allotment of money, etc. related to the merger.

(4) Handling of share acquisition rights and bonds with share acquisition rights in connection with the merger

Not applicable.

3. Overview of companies involved in the merger

	Company surviving the absorption-type merger	Company disappearing in the absorption-type merger
(1) Name	Sysmex Corporation	Sysmex Medica Co., Ltd.
(2) Location	1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe, Hyogo	323-3 Miyaoki, Yumesaki-Cho, Himeji, Hyogo
(3) Job title and name of representative	President Kaoru Asano	President and CEO Emiko Takahashi
(4) Line of businesses	Development, manufacture, sales and export/import of diagnostic instruments, reagents and related software	Assembly of diagnostic instrument units
(5) Share capital	14,887 millions of yen (As of March 31, 2025)	20 millions of yen (As of March 31, 2025)
(6) Date of establishment	February 20, 1968	March 7, 1978
(7) Number of issued shares	629,473,176 shares (As of March 31, 2025)	400 shares (As of March 31, 2025)
(8) Fiscal year-end	March 31	March 31
(9) Major shareholders and percentage of share-holding	The Master Trust Bank of Japan, Ltd. (Trust Account) 12.4% Nakatani Foundation 6.2%	Sysmex Corporation 100%

(As of March 31, 2025)	Custody Bank of Japan, Ltd. (Trust Account) 6.0% The Kobe Yamabuki Foundation 5.7% Nakatani Kosan, Ltd. 5.5%			
(10) Operating results and financial positions for the most recent fiscal year	Fiscal year ended March 31, 2025 (Consolidated, IFRS)		Fiscal year ended March 31, 2025 (Non-consolidated, JGAAP)	
	Equity attributable to owners of the parent	463,776 millions of yen	Net assets	622 millions of yen
	Total assets	665,268 millions of yen	Total assets	935 millions of yen
	Equity attributable to owners of the parent per share	743.71 yen	Net assets per share	1,555,174.55 yen
	Net sales	508,643 millions of yen	Net sales	2,482 millions of yen
	Operating profit	87,583 millions of yen	Operating profit	196 millions of yen
	Profit before tax	79,221 millions of yen	Ordinary profit	198 millions of yen
	Profit attributable to owners of the parent	53,669 millions of yen	Net income	134 millions of yen
	Earnings per share (basic)	86.07 yen	Net income per share	336,684.12 yen

(Note: Percentage of shareholding excludes treasury stock.)

4. Status after the merger

There will be no changes in the name, location, job title and name of representative, description of business, share capital and fiscal year-end of the Company after the merger.

5. Future outlook

Since this is a merger with a wholly owned subsidiary of the Company, the impact on the Company consolidated financial results will be minor.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.